SAN DIEGO, Jan. 22, 2015 (GLOBE NEWSWIRE) -- AltheaDx, Inc. ("AltheaDx" or the "Company"), a commercial stage molecular diagnostics company specializing in the field of personalized medicine, today announced the appointment of Noah Nasser as Senior Vice President of Sales, effective February 2, 2015. Mr. Nasser will report to Greg Hamilton, Chief Executive Officer of AltheaDx.
Mr. Nasser brings more than 20 years of commercial and managerial experience within the diagnostic, medical device and life science fields. Prior to joining AltheaDx, Mr. Nasser was the Global Sales Leader for Verinata Health, a CLIA-certified, CAP-accredited molecular testing provider focused on prenatal testing, that was acquired by Illumina in 2013. As Vice President of Sales and Market Development at Verinata, Mr. Nasser was responsible for global commercialization of the verifi® prenatal test.
Prior to joining the executive team at Verinata, Mr. Nasser was the Business Unit Manager for Molecular Diagnostics at Quidel Corporation. In this role, he led the development and implementation of the company's strategic plan for molecular diagnostics. He directed the activities of commercial, operational and R&D teams, including the development of novel infectious disease assays for respiratory viruses on multiple test platforms. While at Quidel, Mr. Nasser also served as General Manager of the Specialty Products Group, where his focus was the development and commercialization of diagnostic and research products for women's health. Mr. Nasser has held additional leadership positions in sales and marketing at Quidel and at Wako Diagnostics. He holds a B.S. in Molecular Biology from University of California, San Diego.
"We are very pleased to welcome Noah to the company," said Greg Hamilton, Chief Executive Officer. "The breadth and depth of his experience will be instrumental in our efforts to grow our business and continue to increase adoption of our IDgenetix tests, particularly within healthcare institutions. We are fortunate to have a veteran with Noah's credentials join us in our mission to enable healthcare providers to make timely and evidence-based decisions, which we believe can reduce the overall cost of patient care by reducing adverse events, optimizing patients' overall therapeutic regimen and helping to achieve a faster therapeutic response."
"This is a very exciting time to be joining AltheaDx as the company builds on the momentum of its first full year of commercial sales of its IDgenetix tests," said Mr. Nasser. "I look forward to working closely with Greg and the entire AltheaDx team to further accelerate its commercial growth."
AltheaDx is a commercial stage molecular diagnostics company which focuses on enabling physicians, managed care organizations, pharmaceutical companies and other healthcare entities to make personalized therapeutic decisions for patients. AltheaDx's IDgenetix pharmacogenetic testing portfolio addresses some of the most prevalent clinical conditions in the United States, including cardiovascular disease, neuropsychiatric disorders and pain. AltheaDx is a CAP-accredited, CLIA-certified laboratory located in San Diego, CA.
Forward Looking Statements
This press release may contain forward-looking statements regarding the business strategy of AltheaDx. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that could cause actual levels of activity or performance to differ materially from those expressed or implied by these forward looking statements. These statements reflect the views of AltheaDx as of the date of this press release with respect to future events and, except as required by law, it undertakes no obligation to update or revise publicly any forward looking statements, whether as a result of new information, future events or otherwise after the date of this press release.
CONTACT: Kristen Nungesser ICR, Inc. (646) 277-1261 firstname.lastname@example.orgSource:AltheaDx, Inc.